CPC C07C 65/19 (2013.01) [C07C 49/513 (2013.01); C07C 63/49 (2013.01); C07C 63/64 (2013.01); C07C 65/10 (2013.01); C07C 65/17 (2013.01); C07C 65/24 (2013.01); C07C 65/40 (2013.01); C07C 211/55 (2013.01); C07C 215/74 (2013.01); C07C 233/65 (2013.01); C07C 233/81 (2013.01); C07C 317/32 (2013.01); C07C 323/62 (2013.01); C07D 209/18 (2013.01); C07D 213/55 (2013.01); C07D 257/04 (2013.01); C07D 263/32 (2013.01); C07D 277/30 (2013.01); C07D 295/088 (2013.01); C07D 295/16 (2013.01); C07D 333/24 (2013.01); C07C 2601/16 (2017.05); C07C 2602/08 (2017.05)] | 4 Claims |
1. A compound defined by the formula:
or a pharmaceutically acceptable salt, wherein
i) R8, R9, R10, R11, R5 and R4 are hydrogen and R6 is methyl; or
ii) R8, R9, R10, R11, R6, and R5 are hydrogen and R4 is methyl; or
iii) R8, R9, R10, R11, R6, and R5 are hydrogen and R4 is chloro or floro; or
iv) R8, R9, R10, R11, and R6 are hydrogen, R5 is methyl and R4 is methoxy; or
v) R8, R9, R10, R11, and R5 are hydrogen, R6 is methyl and R4 is hydroxy; or
vi) R8, R9, R10, R11, R6, and R5 are hydrogen and R4 is 2-(morpholin-4-yl)ethoxy; or
vii) R8, R9, R10, R11, R6, and R4 are hydrogen and R5 is 2-(morpholin-4-yl)ethoxy; or
viii) R8, R9, R10, R11, R5, and R4 are hydrogen and R6 is 2-(morpholin-4-yl)ethoxy.
|